Log in to search using one of your social media accounts:

 

Drug Keytruda May Help Block Melanoma's Return

The drug also gained attention after former President Jimmy Carter announced in 2015 that Keytruda had beaten back his brain cancer.
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

Conclusion We report the clinical and genomic landscape of a patient with MPTs who had no identifiable unique somatic or germline mutations to explain her predilection to cancer. The treatment course and overall prognosis for this patient is important for understanding future cases with unrelated, metachronous MPTs, the occurrence of which cannot always be explained by underlying genetic mechanisms.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
AbstractPatients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. We find that for the majority of primary and treated metastatic brain tumors, the risk of spontaneous bleeding is acceptable and not further increased by careful therapeutic anticoagul...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Neuro-Oncology, Symptom Management and Supportive Care Source Type: research
Brain metastases (BM) are the most common intracranial neoplastic disease in adults, with an incidence of 9-17% among all brain tumors (Nayak et al., 2012). They are usually caused by lung cancer (either non-small cell (NSCLC) and small cell (SCLC) histologies), breast cancer, melanoma and renal cell carcinoma, with a raising incidence related to the improvements in diagnostic and treatment approaches (Berghoff et al., 2014). However, prognosis remains poor, with a median overall survival (OS) ranging from 3 to 27 months (Brastianos et al., 2013), rendering BM still an unmet medical need.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research
ConclusionPatients who do not respond to one immunotherapy combination may respond during treatment with an alternate combination, even in the presence of multiple brain metastases. Biomarkers are needed to assist clinicians in evidence based clinical decision making after progression on first line immunotherapy to determine whether response can be achieved with second line immunotherapy.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Authors: Winer A, Bodor JN, Borghaei H Abstract Immunotherapy has revolutionized the field of oncology. By inhibiting the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways, multiple studies have demonstrated greatly improved survival in locally advanced and metastatic cancers including melanoma, renal, lung, gastric, and hepatocellular carcinoma. Trials in other malignancies are ongoing, and undoubtedly the number of drugs in this space will grow beyond the six currently approved by the Food and Drug Administration. However, by altering the immune response t...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Molecules, Vol. 23, Pages 702: Bridging from Brain to Tumor Imaging: (S)-(−)- and (R)-(+)-[18F]Fluspidine for Investigation of Sigma-1 Receptors in Tumor-Bearing Mice Molecules doi: 10.3390/molecules23030702 Authors: Mathias Kranz Ralf Bergmann Torsten Kniess Birgit Belter Christin Neuber Zhengxin Cai Gang Deng Steffen Fischer Jiangbing Zhou Yiyun Huang Peter Brust Winnie Deuther-Conrad Jens Pietzsch Sigma-1 receptors (Sig1R) are highly expressed in various human cancer cells and hence imaging of this target with positron emission tomography (PET) can contribute to a better understandi...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Authors: Brown L, David J, Skopit S Abstract Basal cell carcinoma (BCC) is a common skin malignancy comprising 80% of non-melanoma skin cancers.1 Over 2.8 million cases are estimated to be diagnosed in the United States alone each year. Advanced BCCs are comprised of BCCs that have metastasized to local or distant lymph nodes or organs, or locally invasive BCCs that are extensive and infiltrate vital structures such as eyes, nose, or brain. Advanced BCC tumors represent roughly 1-10% of BCCs today. Two severe case presentations and treatment options will be discussed in this case report series and review. J Drugs D...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
CONCLUSIONS: The results can be useful for economists to define the health priorities in each country, make the financial decisions in economics, and thus contribute to better health, economic growth, as well as effective spending of health expenditures. PMID: 29524371 [PubMed - in process]
Source: Central European Journal of Public Health - Category: International Medicine & Public Health Tags: Cent Eur J Public Health Source Type: research
CONCLUSIONS: A novel oHSV encoding GADD34 is efficacious and relatively nontoxic in mouse models of GBM. PMID: 29511029 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Prognosis of patients with melanoma brain metastasis is poor despite various chemotherapeutic agents. Researchers focus on finding effective treatment with low risk of toxicity. Thymoquinone (TQ) has been found to be effective on different types of cancer. However, no data exists on the effect of TQ in intracerebral melanoma. The purpose of this study was to assess the effect of TQ in B16-F10 melanoma cell in vitro and intracerebral melanoma in vivo.
Source: World Neurosurgery - Category: Neurosurgery Authors: Tags: Original article Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Health | Melanoma | Neurology | Skin Cancer